title: Gene therapy of the brain: the trans-vascular approach.
abstract: Many chronic neurologic diseases do not respond to small molecule therapeutics, and have no effective long-term therapy. Gene therapy offers the promise of an effective cure for both genetic and acquired brain disease. However, the limiting problem in brain gene therapy is delivery to brain followed by regulation of the expression of the transgene. Present day gene vectors do not cross the blood-brain barrier (BBB). Consequently, brain gene therapy requires craniotomy and the local injection of a viral gene vector. However, there are few brain disorders that can be effectively treated with local injection. Most applications of gene therapy require global expression in the brain of the exogenous gene, and this can only be achieved with a noninvasive delivery through the BBB--the trans-vascular route to brain. An additional consideration is the potential toxicity of all viral and nonviral approaches, which may either integrate into the host genome and cause insertional mutagenesis or cause inflammation in the brain. Nonviral, noninvasive gene therapy of the brain is now possible with the development of a new approach to targeting therapeutic genes to the brain following an IV administration. This approach utilizes genetically engineered molecular Trojan horses, which ferry the gene across the BBB and into neurons. Global and reversible expression of therapeutic genes in the human brain without surgery and without viral vectors is now possible.
authors.affiliation: Department of Neurology, University of Regensburg, Germany.
authors.forename: Felix
authors.initials: F
authors.lastname: Schlachetzki
authors.forename: Yun
authors.initials: Y
authors.lastname: Zhang
authors.forename: Ruben J
authors.initials: RJ
authors.lastname: Boado
authors.forename: William M
authors.initials: WM
authors.lastname: Pardridge
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier / Q000503:physiopathology; D001921:Brain / Q000098:blood supply* / Q000187:drug effects / Q000503:physiopathology; D001927:Brain Diseases / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D002560:Cerebrovascular Circulation / Q000235:genetics; D003399:Craniotomy; D004337:Drug Carriers / Q000627:therapeutic use; D005786:Gene Expression Regulation; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends*; D005822:Genetic Vectors / Q000235:genetics / Q000627:therapeutic use; D006801:Humans
chemical_list: D004337:Drug Carriers